The clinical application value of predicting BRAF and TERT promoter mutations of thyroid cancer in ultrasound images based on artificial intelligence methods

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100044902

Enrollment

Unknown

Registered

2021-03-31

Start date

2021-03-30

Completion date

Unknown

Last updated

2021-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid cancer

Interventions

Gold Standard:Postoperative pathological results.

Index test:Ultrasonic&#32

images,&#32

artificial&#32

intelligence&#32

method.

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. The corresponding nodules were surgically removed and pathologically confirmed to be thyroid cancer; 2. Received Tert and BRAF genetic tests; 3. Ultrasound examination was performed three months before surgery; 4. The gray-scale image quality of the long axis and short axis of the maximum section can be achieved; 5. No other treatment (ablation, radiotherapy, chemotherapy, etc.) was performed before ultrasound examination.

Exclusion criteria

Exclusion criteria: 1. Pathological non-PTC cases; 2. Incomplete clinical data; 3. Ultrasonic image cannot meet the requirement.

Design outcomes

Primary

Measure	Time frame
BARF+TERT promoter mutation of thyroid cancer ;SEN, SPE, ACC, AUC of ROC;	—

Countries

China

Contacts

Public ContactXu Huixiong

Shanghai Tenth People's Hospital

xuhuixiong@126.com+86 18917683519

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026